ACS Medicinal Chemistry Letters · 2022 · 49 citations · 17 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyChemical Library DesignCovalent Drug DesignCovalent Inhibitor DesignLibrary DesignLigand BindingBruton Tyrosine KinaseCovalent InhibitorsCovalent Kinase InhibitorsCovalent Library DesignDna-encoded LibrariesDna-encoded Library DesignDna-encoded Library TechnologyTyrosine Kinase Inhibition
Since ibrutinib was approved by the FDA as an effective monotherapy for chronic lymphocytic leukemia (CLL) and multilymphoma, more and more FDA-approved covalent drugs are coming back into the market. On this occasion, the resurgence of interest in covalent drugs calls for more hit discovery techniques. However, the limited numbers of covalent libraries prevent the development of this area. Herein, we report the design of covalent DNA-encoded library (DEL) and its selection method for the discovery of covalent inhibitors for target proteins. These triazine-based covalent DELs yielded potent compounds after covalent selection against target proteins, including Bruton's Tyrosine Kinase (BTK), Janus kinase 3 (JAK3), and peptidyl-prolyl cis/trans isomerase NIMA-interacting-1 (Pin1).
17
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text
Proteome-wide covalent ligand discovery in native biological systems
Keriann M. Backus, Bruno E. Correia, Kenneth M. Lum et al. · Nature · 2016 · 978 citations
D.E. Mortenson, Gabriel J. Brighty, Lars Plate et al. · Journal of the American Chemical Society · 2017 · 305 citations · Full text
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Kazuhiro Koikawa, Shin Kibe, Futoshi Suizu et al. · Cell · 2021 · 241 citations · Full text
Medicine, Immunology, Oncology +11